WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced that its Founder and Chief Executive Officer, Wes Kaupinen, will take part in a fireside chat at the Jones Healthcare and Technology Innovation Conference. The discussion is scheduled for Wednesday, April 9, 2025, at 2:00 p.m. PT.
The live event will be streamed via webcast, with an archived replay available for approximately 90 days afterward on Palvella’s Events and Presentations page.
Palvella, a clinical-stage biopharmaceutical company, is known for its focus on developing treatments for rare genetic skin diseases that currently lack FDA-approved therapies. Its work is centered around the QTORIN™ platform, a proprietary technology designed to address these underserved conditions.
The company’s lead investigational product, QTORIN™ rapamycin 3.9% anhydrous gel, is being tested in two clinical trials. The Phase 3 SELVA trial investigates its use in microcystic lymphatic malformations, while the Phase 2 TOIVA trial evaluates potential treatment for cutaneous venous malformations.
While QTORIN™ rapamycin remains under investigation and is not yet FDA-approved, its development underscores Palvella’s commitment to addressing the unmet needs of patients with rare genetic skin diseases.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.